New resource available view now
New resource available view now
Recent Post
Related Posts
IGC Pharma Announces Equity Research Update by Alliance Global Partners
POTOMAC, MARYLAND – February 10, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that Alliance Global Partners (“AGP”) has published an updated equity research report covering the Company. The report reiterates a Buy rating and includes a price target of $3.00 per share. All statements, opinions,
IGC Pharma Expands Phase 2 CALMA Trial into Colombia’s Premier Alzheimer’s Research Center
POTOMAC, Maryland – February 09, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced the expansion of its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America, through the addition of Grupo de Neurociencias de Antioquia (“GNA”). This expansion marks a pivotal operational milestone as IGC enters a region internationally recognized for its unique, genetically linked Alzheimer’s population. The GNA site is the latest addition to a
POTOMAC, MARYLAND – February 2, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer’s disease.
POTOMAC, MARYLAND – January 22, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (“AI”) to develop innovative treatments for Alzheimer’s disease, today announced the addition of Integrative Clinical Trials,
Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities